UroGen Pharma Ltd. (URGN) Stock Analysis and Metrics

UroGen Pharma

NASDAQ: URGN

$40.97 ▼ -1.53 (-3.60%)

At close: Jul 24, 2026 · 4:00 PM UTC

Financial Ratios

Market Cap2.05 Bn

P/E-15.41

P/S14.62

Div. Yield0.00

Total Debt (Qtr)189.53 Mn

Revenue Growth (1y) (Qtr)151.60

Add ratio to table…

About

UroGen Pharma Ltd. is a biotechnology company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company’s core technology is the RTGel reverse thermal hydrogel platform, which enables sustained release of drugs in the urinary tract. Its pipeline includes next generation formulations such as UGN 103 and UGN 104, as well as the oncolytic virus UGN 501. The company invests heavily in research and development to advance its pipeline and expand the applicability of its RTGel platform beyond urothelial cancers.

The company generates revenue primarily from the sale of its two FDA approved products, Jelmyto (mitomycin for pyelocalyceal solution) and Zusduri (mitomycin for intravesical solution), which are distributed through wholesalers, specialty pharmacies and directly to hospitals and clinics. In addition, the company has entered into licensing and supply agreements that may provide milestone payments and royalties upon successful development and commercialization of pipeline candidates. Product sales account for the substantial majority of total revenue, while collaboration agreements contribute potential future milestone and royalty income.

UroGen Pharma Ltd. occupies a specialized niche in the uro oncology sector as the first and only provider of FDA approved nonsurgical therapies for low grade upper tract urothelial cancer and recurrent low grade intermediate risk non muscle invasive bladder cancer. The company competes with large multinational pharmaceutical corporations such as AstraZeneca, Bristol Myers Squibb, GSK, Johnson & Johnson, Merck, Pfizer and Roche, as well as focused biotechnology firms including Aura Biosciences, CG Oncology, Ferring Pharmaceuticals and ImmunityBio. Its competitive advantages stem from the proprietary RTGel technology that prolongs drug exposure in the urinary tract, the orphan drug exclusivity granted for Jelmyto, a broad patent portfolio covering its hydrogel platform and product formulations, and an experienced leadership team with deep backgrounds in oncology and urology. These factors enable UroGen to offer differentiated therapies that aim to reduce reliance on repeated surgical procedures and improve patient outcomes. The addressable patient populations for its approved products are estimated in the tens of thousands annually in the United States, reflecting significant unmet medical need.

The company's customers consist of hospitals, outpatient surgery centers, urology and oncology clinics, and the patients treated by these providers. In the United States, its products are distributed through wholesalers, specialty pharmacy chains and directly to medical facilities. UroGen also engages with group purchasing organizations and integrated delivery networks to secure formulary placement and reimbursement access. While the current commercial focus is on the US market, the company explores opportunities to expand its reach through partnerships with international distributors. These customers include academic medical centers, community hospitals and private urology practices that prescribe Jelmyto and Zusduri for appropriate patient populations.

Investment Thesis

▲ Bull case

UroGen's ZUSDURI launch is demonstrating robust and sustainable growth driven by accelerating commercial metrics that significantly outpace industry analogs like ANKTIVA, with Q1 revenue of $29.2 million representing over 100% quarter-over-quarter growth following the permanent J-code implementation in January 2026. The company is seeing consistent expansion in both unique and repeat prescribers, increasing from 102 to 256 unique prescribers and 32 to 103 repeat prescribers year-over-year, indicating deepening healthcare provider confidence and successful integration into routine urology practice beyond initial adopters. Crucially, patient enrollment forms (PEFs) continue to show sequential growth, reflecting strong top-of-funnel demand that is translating into new patient starts and revenue, with conversion timelines improving from 45-60 days in Q4 to 30-35 days in Q1 and trending toward the 2-3 week range seen with JELMYTO, signaling operational efficiency gains as workflow integration progresses. The shift toward community practice utilization is particularly significant, as approximately 70% of the $5 billion annual market opportunity for recurrent low-grade intermediate risk non-muscle invasive bladder cancer resides in this setting, and UroGen has already moved from a 60% hospital/40% community mix in Q4 to nearly 50-50 by Q1 end, positioning the company to capture the majority of addressable patients as community adoption accelerates. With open access to more than 95% of covered lives and reimbursement confidence bolstered by the permanent J-code, UroGen is well-positioned to leverage its differentiated value proposition as the first and only FDA-approved nonsurgical therapy offering durable complete response rates of approximately 80% at 3 months and 72% event-free probability at 24 months, which directly addresses the high treatment burden of repeated TURBT procedures in this patient population. Management's strategy to expand commercial efforts toward direct patient engagement—highlighting ZUSDURI's ability to provide recurrence-free and treatment-free living—could unlock additional demand velocity, especially as patients become increasingly aware of alternatives to surgery and maintenance therapy. The pipeline remains a critical long-term catalyst, with UGN-103 progressing toward an NDA submission in the second half of 2026 based on Phase III UTOPIA trial data showing a 77.8% complete response rate at 3 months, and potential approval in 2027 that could extend the franchise into adjuvant and high-grade settings, while UGN-501's IND-enabling studies nearing completion support a Phase I trial in NMIBC by year-end, diversifying beyond mitomycin-based therapies. Financially, UroGen maintains a strong balance sheet with approximately $140 million in cash, cash equivalents, and marketable securities as of March 31, 2026, following the Pharmakon Advisors term loan refinancing, providing ample runway to support ZUSDURI's launch, pipeline advancement, and path to profitability without immediate dilution concerns. UroGen

UroGen's ZUSDURI launch is demonstrating robust and sustainable growth driven by accelerating commercial metrics that significantly outpace industry analogs like ANKTIVA, with Q1 revenue of $29.2 million representing over 100% quarter-over-quarter growth following the permanent J-code implementation in January 2026. The company is seeing consistent expansion in both unique and repeat prescribers, increasing from 102 to 256 unique prescribers and 32 to 103 repeat prescribers year-over-year, indicating deepening healthcare provider confidence and successful integration into routine urology practice beyond initial adopters. Crucially, patient enrollment forms (PEFs) continue to show sequential growth, reflecting strong top-of-funnel demand that is translating into new patient starts and revenue, with conversion timelines improving from 45-60 days in Q4 to 30-35 days in Q1 and trending toward the 2-3 week range seen with JELMYTO, signaling operational efficiency gains as workflow integration progresses. The shift toward community practice utilization is particularly significant, as approximately 70% of the $5 billion annual market opportunity for recurrent low-grade intermediate risk non-muscle invasive bladder cancer resides in this setting, and UroGen has already moved from a 60% hospital/40% community mix in Q4 to nearly 50-50 by Q1 end, positioning the company to capture the majority of addressable patients as community adoption accelerates. With open access to more than 95% of covered lives and reimbursement confidence bolstered by the permanent J-code, UroGen is well-positioned to leverage its differentiated value proposition as the first and only FDA-approved nonsurgical therapy offering durable complete response rates of approximately 80% at 3 months and 72% event-free probability at 24 months, which directly addresses the high treatment burden of repeated TURBT procedures in this patient population. Management's strategy to expand commercial efforts toward direct patient engagement—highlighting ZUSDURI's ability to provide recurrence-free and treatment-free living—could unlock additional demand velocity, especially as patients become increasingly aware of alternatives to surgery and maintenance therapy. The pipeline remains a critical long-term catalyst, with UGN-103 progressing toward an NDA submission in the second half of 2026 based on Phase III UTOPIA trial data showing a 77.8% complete response rate at 3 months, and potential approval in 2027 that could extend the franchise into adjuvant and high-grade settings, while UGN-501's IND-enabling studies nearing completion support a Phase I trial in NMIBC by year-end, diversifying beyond mitomycin-based therapies. Financially, UroGen maintains a strong balance sheet with approximately $140 million in cash, cash equivalents, and marketable securities as of March 31, 2026, following the Pharmakon Advisors term loan refinancing, providing ample runway to support ZUSDURI's launch, pipeline advancement, and path to profitability without immediate dilution concerns. UroGen

▼ Bear case

Despite strong early ZUSDURI growth, UroGen faces significant risks in sustaining momentum due to the nascent stage of commercialization and limited market penetration, with only 300 unique prescribers against a target of 8,500 healthcare providers, indicating the company remains in the very early stages of its rollout plan and heavily reliant on a narrow base of early adopters, including over 50% overlap with existing JELMYTO users, which raises concerns about the ability to achieve broad-based adoption beyond the current commercial footprint. The improvement in conversion timelines from PEF to treatment initiation—while positive—is still at 30-35 days in Q1, well above the 2-3 week benchmark for established products like JELMYTO, suggesting persistent operational and workflow integration challenges in both community and academic settings that could slow patient access and dampen physician enthusiasm as the novelty of initial results wears off. Reimbursement dynamics remain a critical vulnerability, as although open access covers over 95% of covered lives, the company acknowledged that ZUSDURI's $130,000 price point still triggers cost sensitivity discussions, particularly as payers may scrutinize the value proposition compared to lower-cost alternatives or emerging adjuvant therapies, and management's reliance on anecdotal evidence about patient preference for nonsurgical options does not guarantee sustained formulary placement or preferential reimbursement in an increasingly cost-constrained healthcare environment. The long-term durability of ZUSDURI's clinical benefit, while impressive in the ENVISION trial with a median duration of response not reached at 23.7 months follow-up, lacks real-world validation at scale, and any discrepancy between trial results and community practice outcomes—especially in patients with higher recurrence risk or comorbidities—could erode physician confidence and limit uptake beyond highly motivated early adopters. Pipeline execution carries substantial risk, as UGN-103's NDA submission in the second half of 2026 depends on 6-month durability data from the UTOPIA trial, with plans to update the filing using 12-month data later, creating potential for regulatory delays if durability does not hold, and the planned Type C meetings with the FDA in Q2 2026 for adjuvant and high-grade trials introduce uncertainty about trial design acceptance, enrollment timelines, and the ability to initiate Phase III studies by year-end as stated. UGN-501's development as an oncolytic virus therapy remains highly speculative, with IND-enabling studies nearing completion but no clinical data yet, and its proposed mechanism—mimicking chemotherapy before delivering immunomodulatory benefit—lacks differentiation in a crowded oncolytic virus space, raising questions about its competitive advantage and likelihood of success in Phase I trials. Financially, while Q1 SG&A expenses increased to $51.5 million from $35 million year-over-year due to commercial expansion and one-time refinancing costs, management's expectation that Q1 represents the high point for SG&A in 2026 hinges on successful phasing of activities and the absence of further one-time expenses, but any additional costs related to debt refinancing, commercial expansion, or pipeline setbacks could pressure operating margins and extend the path to profitability beyond current expectations. UroGen

Despite strong early ZUSDURI growth, UroGen faces significant risks in sustaining momentum due to the nascent stage of commercialization and limited market penetration, with only 300 unique prescribers against a target of 8,500 healthcare providers, indicating the company remains in the very early stages of its rollout plan and heavily reliant on a narrow base of early adopters, including over 50% overlap with existing JELMYTO users, which raises concerns about the ability to achieve broad-based adoption beyond the current commercial footprint. The improvement in conversion timelines from PEF to treatment initiation—while positive—is still at 30-35 days in Q1, well above the 2-3 week benchmark for established products like JELMYTO, suggesting persistent operational and workflow integration challenges in both community and academic settings that could slow patient access and dampen physician enthusiasm as the novelty of initial results wears off. Reimbursement dynamics remain a critical vulnerability, as although open access covers over 95% of covered lives, the company acknowledged that ZUSDURI's $130,000 price point still triggers cost sensitivity discussions, particularly as payers may scrutinize the value proposition compared to lower-cost alternatives or emerging adjuvant therapies, and management's reliance on anecdotal evidence about patient preference for nonsurgical options does not guarantee sustained formulary placement or preferential reimbursement in an increasingly cost-constrained healthcare environment. The long-term durability of ZUSDURI's clinical benefit, while impressive in the ENVISION trial with a median duration of response not reached at 23.7 months follow-up, lacks real-world validation at scale, and any discrepancy between trial results and community practice outcomes—especially in patients with higher recurrence risk or comorbidities—could erode physician confidence and limit uptake beyond highly motivated early adopters. Pipeline execution carries substantial risk, as UGN-103's NDA submission in the second half of 2026 depends on 6-month durability data from the UTOPIA trial, with plans to update the filing using 12-month data later, creating potential for regulatory delays if durability does not hold, and the planned Type C meetings with the FDA in Q2 2026 for adjuvant and high-grade trials introduce uncertainty about trial design acceptance, enrollment timelines, and the ability to initiate Phase III studies by year-end as stated. UGN-501's development as an oncolytic virus therapy remains highly speculative, with IND-enabling studies nearing completion but no clinical data yet, and its proposed mechanism—mimicking chemotherapy before delivering immunomodulatory benefit—lacks differentiation in a crowded oncolytic virus space, raising questions about its competitive advantage and likelihood of success in Phase I trials. Financially, while Q1 SG&A expenses increased to $51.5 million from $35 million year-over-year due to commercial expansion and one-time refinancing costs, management's expectation that Q1 represents the high point for SG&A in 2026 hinges on successful phasing of activities and the absence of further one-time expenses, but any additional costs related to debt refinancing, commercial expansion, or pipeline setbacks could pressure operating margins and extend the path to profitability beyond current expectations. UroGen

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	67,072.09 Bn	-31.30 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,894.61 Bn	0.00 Bn	56,599.40	0.11 Bn
3	AKTX	Akari Therapeutics Plc	1,014.18 Bn	0.00 Bn	-	-
4	ONC	BeOne Medicines Ltd.	471.64 Bn	0.00 Bn	82.18	0.96 Bn
5	VRTX	Vertex Pharmaceuticals Inc / Ma	121.72 Bn	0.00 Bn	9.96	-
6	REGN	Regeneron Pharmaceuticals, Inc.	68.28 Bn	0.00 Bn	4.58	1.99 Bn
7	BLTE	Belite Bio, Inc	61.40 Bn	361.18 Bn	-	-
8	ARGX	Argenx Se	56.94 Bn	0.00 Bn	12.22	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password